Visudyne Injection
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Visudyne Injection contains verteporfin, a light-activated medicine used in photodynamic therapy. Its labelling describes it for the treatment of the wet (neovascular) form of age-related macular degeneration and other conditions causing abnormal blood vessels under the retina. It is given as an intravenous infusion followed by treatment with a special laser, under the supervision of an eye specialist.
Product Information
The following description reflects information associated with verteporfin and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for photodynamic therapy of the wet (neovascular) form of age-related macular degeneration
- Described for other conditions causing abnormal blood vessels under the retina
- Described as accumulating in the abnormal blood vessels, where light activation damages their lining and closes them
Described Dosage & Administration
- Administered only by a doctor or nurse as an intravenous infusion, followed by laser treatment — not self-administered
- The composition should be checked for any component the patient is allergic to before administration
- Given under the supervision of an eye specialist
Described Side Effects
Commonly described side effects include:
- Injection-site reaction
- Visual disturbance, blurred or decreased vision, and double vision
- Eye itching, conjunctivitis, and eyelid inflammation
- Photosensitivity (increased sensitivity to light)
- Headache and weakness
- High blood pressure
- Back pain
Increased sensitivity to light is described for a period after treatment; strong light and direct sunlight should be avoided as advised. Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- The medicine is described as causing dizziness, so driving and tasks needing full focus should be avoided afterwards
- The injection composition should be checked for allergies before administration
- Exposure to bright light and direct sunlight should be limited for the period advised after treatment
- Any persistent or severe side effect should be reviewed by a clinician
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains verteporfin and is used in photodynamic therapy for the wet (neovascular) form of age-related macular degeneration and other causes of abnormal retinal blood vessels. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling states it is administered by a doctor or nurse as an intravenous infusion followed by laser treatment, under the supervision of an eye specialist. It is not self-administered.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.